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An open letter from Professor John Strang, chair of the clinical guidelines update 
working group 
 
22 July 2015 
 
 
Dear colleagues, 
 
Naloxone – preliminary advice from the working group updating Drug Misuse and 
Dependence: UK Guidelines on Clinical Management 
Background 
An NHS England Patient Safety Alerti in 2014 raised questions about naloxone dosing in 
overdose situations. There have also been questions about take-home naloxone products 
that can be supplied and training that should be provided, now and following legislation to 
make naloxone more widely available from October 2015 onwards. 
The 2007 national clinical guidelinesii are currently being updated and a new edition will be 
published in 2016. The working group updating the clinical guidelines has decided to publish 
some preliminary advice on these naloxone questions before addressing its supply and use 
more fully in the published update next year. 
This advice was developed by a small subgroup led by Dr Ed Day, to whom I am grateful. 
Naloxone and its use 
Across Europe, illicit opioid users are 10 times more likely to die than their peers of the same 
age group and gender, and 6,100 deaths were attributed directly to opioid overdose in 2012. 
Naloxone is a potentially life-saving medicine when used in settings associated with opiate 
misuse and overdose. There is evidence that take-home naloxone given to service users, 
and training family members or peers in how to administer naloxone, can be effective in 
reversing heroin overdoses. Its legal status means that anyone can administer naloxone for 
the purpose of saving a life, and it has been supplied by some drug treatment services since 
2005. 
However naloxone is only licensed for use in injectable form and remains a prescription-only 
medicine. This means that at present it can only be distributed to patients with a prescription 
or via an alternative mechanism (patient group direction (PGD) or patient specific direction 
(PSD)). 
Naloxone is an opioid/opiate antagonist and is already licensed for use in: 
1. complete or partial reversal of central nervous system depression and especially 
respiratory depression, caused by natural or synthetic opioids; and 
2. treatment of suspected acute opioid overdose or intoxication. 
An NHS England Patient Safety Alerti in November 2014 highlighted risks associated with the 
use of naloxone in patients where it is not indicated, or in larger than recommended doses. 
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Naloxone dosing 
UK Medicines Information (UKMi) Q&A document on naloxoneiii highlights that there are two 
distinct scenarios where naloxone may be used, and that appropriate dosing needs to be 
mindful of a range of patient factors (including the scenario). 
The first scenario is palliative care which is not the focus of this letter. 
The second is the case of drug misuse and dependence. In an emergency scenario where 
an individual has used sufficient opioid to reduce their rate of respiration to life-threatening 
levels, prompt administration of naloxone can reverse these effects and restore adequate 
levels of oxygen in the bloodstream. The risks of giving too much naloxone when it is not 
required are well documented (see box) but the UKMi document is clear that, in the reversal 
of acute opioid toxicity with severe respiratory depression or arrest, ‘Higher initial dose 
regimens’ are of particular value. 
The recommended intramuscular dose is 400 micrograms initially, with further 400 
microgram doses given incrementally every 2-3 minutes until an effect is noted or the 
ambulance arrives. 
Total available naloxone in a community overdose situation before an ambulance arrives is 
unlikely to exceed 2mg (five 400 microgram doses), which is the amount at which the BNF 
recommends the diagnosis of opiate overdose should be reviewed. 
Risks of giving too much naloxone 
Acute withdrawal syndrome from opioids can have both unpleasant and potentially serious 
effects. Physical effects such as vomiting, agitation, shivering, sweating, tremor and 
tachycardia are unpleasant, and may lead to aggression and a refusal to accept further 
treatment (i.e. refusal to go in ambulance or to stay in hospital). Furthermore, life threatening 
withdrawal reactions may also occur in as many as 1% of cases of naloxone administration, 
with the potential to cause a sympathetic excess and resultant pulmonary oedema and 
ventricular arrhythmia. 
Naloxone products 
A number of products are licensed for use in reversing acute opioid overdose, and all have 
both advantages and disadvantages in terms of assembly, dose, dose calculation and ease 
of administration. Consideration should also be given to storage and transportation of the 
product when identifying the appropriate product to supply. 
One product (Prenoxad) has a licence that specifies use in community settings, and comes 
in a pre-filled syringe containing five 400-microgram doses. 
UKMi is producing a product safety assessment report on naloxone products used in 
emergency situations, which will guide on the issues associated with giving different 
naloxone products in practice.  
It is essential that a minimum level of training in how to assemble and use the particular 
product should be given to complement provision of that product. Other training will also be 
helpful. 
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Training 
There is already advice from Public Health Englandiv that training need not be complicated, 
but it should cover the identification of overdose and how to then respond to overdose. This 
should certainly cover first calling an ambulance. Where a naloxone product is supplied a 
minimum level of training in how to assemble and use that product should be given. 
People being trained in how to respond to opiate overdose, including using any available 
naloxone, should, after training, be able to demonstrate an understanding of the following: 
• How to identify a suspected opiate overdose 
• When to call 999 
• Rescue breathing, cardiopulmonary resuscitation (CPR) and the recovery position 
• What naloxone is: 
 What it does 
 What it can’t do 
 Its short acting nature 
• Using naloxone: 
 When to administer naloxone 
 How to administer naloxone 
• The importance of staying with a casualty 
 
 
Yours faithfully, 
 
 
Professor John Strang 
Chair, Clinical guidelines update working group 
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